The impact of personalized medicine has varied based on tumor types and some of the original developments, specifically in genomics and the identification of biomarkers, had a huge impact on breast cancer treatment, Edmund Pezalla, MD, MPH, thinks.
Pezalla believes that personalized medicine has significantly affected outcomes in breast cancer. “With the discovery of HER2, and the identification of HER2-expressing tumors that responded to specific medications has been a big breakthrough and there have been huge improvements in breast cancer because of that and the discovery of other markers,” he said.
In his opinion, we are still in the learning phase for other tumor types, although lung cancer has seen some breakthroughs. A small number of patients who express the right biomarkers for some of the newer oncology drugs on the market are seeing success. “Not cures necessarily, but success in improving [patient] outcomes, their length of life, and their overall survival, because they have been identified as a candidate for that particular drug.”
The impact of personalized medicine, though, has been felt beyond oncology such as in cystic fibrosis, where certain genetic subtypes are treatable so a patient can lead a normal life and maybe even a normal life span, Pezalla said.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More